The impact of home treatment and self-administration of omalizumab on chronic urticaria

Background: Patients suffering from Chronic Spontaneous Urticaria (CSU) may be recalcitrant to treatment with high dose second-generation antihistamines. These patients are, according to international guidelines, eligible to treatment with omalizumab. Treatment with omalizumab has proven to be very...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:	World Allergy Organization Journal
المؤلفون الرئيسيون:	Anne Christine Wiuff, MBBS, Malthe Alexander Knudsgaard Wiis, MBBS, Sofine Heilskov, MD, Anne Sofie Frølunde, MD, Jennifer Astrup Sørensen, MD, Mette Deleuran, MD, DMSc, Simon Francis Thomsen, MD, PhD, DMSc, Christian Vestergaard, MD, PhD, DMSc
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Elsevier 2022-12-01
الموضوعات:	Chronic spontaneous urticaria Omalizumab Self-administration Home-treatment Patient satisfaction
الوصول للمادة أونلاين:	http://www.sciencedirect.com/science/article/pii/S1939455122001016

مواد مشابهة

Effectiveness of transitioning from omalizumab to dupilumab in chronic spontaneous urticaria patients with inadequate response to omalizumab
حسب: Koremasa Hayama, M.D., Ph.D., وآخرون
منشور في: (2025-08-01)

Does angioedema in patients with chronic spontaneous urticaria impact response to omalizumab?
حسب: Thomas B. Casale, MD, وآخرون
منشور في: (2024-08-01)

Predicting responses to omalizumab in antihistamine-refractory chronic urticaria: A real-world longitudinal study
حسب: Hyun-Young Lee, PhD, وآخرون
منشور في: (2024-05-01)

Mapping the intellectual structure of the research of omalizumab in chronic spontaneous urticaria: A bibliometric analysis
حسب: Yuxu Yao, MD, وآخرون
منشور في: (2024-05-01)

Different doses and courses of omalizumab for patients with chronic spontaneous urticaria: A systematic review with meta-analysis and trial sequential analysis
حسب: Haiyan Qin, MD, وآخرون
منشور في: (2024-04-01)

Rapid response of omalizumab-resistant chronic urticaria to acalabrutinib
حسب: Diamond R. Guy, BS, وآخرون
منشور في: (2024-05-01)

The use of an urticaria control test for the evaluation of omalizumab treatment response in patients diagnosed with chronic urticaria
حسب: Burhan Engin, وآخرون
منشور في: (2020-12-01)

Utilidad clínica del omalizumab en urticaria crónica inducible
حسب: Ricardo Cardona
منشور في: (2018-06-01)

Type I and type IIb autoimmune chronic spontaneous urticaria: Using common clinical tools for endotyping patients with CSU
حسب: Juliana A. Sella, MD, PhD, وآخرون
منشور في: (2023-11-01)

Efficacy and safety of omalizumab against chronic spontaneous urticaria: Real-world study from China
حسب: Ao Wang, MD, وآخرون
منشور في: (2022-12-01)

Factors Influencing Relapse After Omalizumab in Chronic Urticaria. Does the Method of Discontinuation Influence Relapse?
حسب: Petek Üstün, وآخرون
منشور في: (2025-07-01)

Cold urticaria with risk of anaphylaxis treated with omalizumab: a case report
حسب: Tonatiuh Ramses Bedolla-Pulido, وآخرون
منشور في: (2021-02-01)

Omalizumab withdrawal outcomes in chronic spontaneous urticaria are linked with baseline IgE and eosinophil levels
حسب: Ramit Maoz-Segal, MD, وآخرون
منشور في: (2024-05-01)

Cyclosporine for omalizumab-refractory chronic urticaria: a report of five cases
حسب: Anthony F. LaCava, وآخرون
منشور في: (2023-08-01)

Ciclosporina no Tratamento da Urticária Crónica Espontânea na Era do Omalizumab
حسب: Bárbara Roque Ferreira, وآخرون
منشور في: (2018-05-01)

Omalizumab for Chronic Urticaria: A Case Series and Overview of the Literature
حسب: Ilya Ivyanskiy, وآخرون
منشور في: (2012-01-01)

Treatment of chronic urticaria with omalizumab: the experience of Hospital de Braga
حسب: Ana G. Lopes, وآخرون
منشور في: (2022-10-01)

Omalizumab Use in Chronic Spontaneous Urticaria during Pregnancy and a Four Years’ Follow-Up: A Case Report
حسب: Laura Michelina Losappio, وآخرون
منشور في: (2020-10-01)

Progress in the application of omalizumab in the treatment of chronic inducible urticaria
حسب: CHEN Ziyan, وآخرون
منشور في: (2024-12-01)

Retrospective analysis of the treatment of 61 cases of chronic spontaneous urticaria with omalizumab
حسب: Shanshan OU, وآخرون
منشور في: (2023-04-01)

Adverse Reaction to Omalizumab in Patients with Chronic Urticaria: Flare Up or Ineffectiveness?
حسب: Ragıp Ertaş, وآخرون
منشور في: (2016-01-01)

Omalizumab's efficacy and safety against chronic spontaneous urticaria
حسب: Öner Özdemir
منشور في: (2023-08-01)

Multicentric and Observational Study of Omalizumab for Chronic Spontaneous Urticaria in Real-Life in Colombia
حسب: Elizabeth García-Gómez, وآخرون
منشور في: (2022-05-01)

Position statement for the use of omalizumab in the management of chronic spontaneous urticaria in Indian patients
حسب: Kiran Godse, وآخرون
منشور في: (2016-01-01)

Alopecia Areata after Omalizumab Treatment for Chronic Spontaneous Urticaria
حسب: Eli Magen
منشور في: (2019-07-01)

Omalizumab for the management of refractory chronic spontaneous urticaria
حسب: P C Kathuria, وآخرون
منشور في: (2022-01-01)

Omalizumab in the treatment of chronic spontaneous urticaria – literature review and own experience
حسب: Joanna Dawicka, وآخرون
منشور في: (2016-02-01)

Peripheral blood T-cell modulation by omalizumab in chronic urticaria patients
حسب: Cristina López, وآخرون
منشور في: (2024-08-01)

Case Report: Omalizumab for Chronic Spontaneous Urticaria in Pregnancy
حسب: Shuang-Lu Liao, وآخرون
منشور في: (2021-03-01)

IgE as a predictor to omalizumab response in patients with chronic spontaneous urticaria
حسب: Luis Felipe Ensina, وآخرون
منشور في: (2025-01-01)

The effect of COVID-19 pandemic on treatment compliance and process of chronic urticaria patients receiving omalizumab treatment
حسب: Gokhan Aytekin, وآخرون
منشور في: (2021-09-01)

Urticaria crónica idiopática o urticaria espontánea y omalizumab. Revisión del tema a propósito de un caso
حسب: Giovanni Sedó Mejía, وآخرون
منشور في: (2014-05-01)

Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: can we define better-responding endotypes?
حسب: Emek Kocatürk, وآخرون
منشور في: (2022-09-01)

Clinical observation of desloratadine combined with omalizumab in the treatment of chronic spontaneous urticaria
حسب: Zhiwei SHANG, وآخرون
منشور في: (2022-02-01)

Efficiency of Adding Omalizumab to Standard Therapy for Children with Recurrent Spontaneous Urticaria: Comparative Observational Study
حسب: Vera G. Kalugina, وآخرون
منشور في: (2020-08-01)

COVID-19 infection in chronic spontaneous urticaria treated with omalizumab: two case reports
حسب: Angelo Massimiliano D'Erme, وآخرون
منشور في: (2023-08-01)

Comparison of long term efficacy and cost-effectiveness of omalizumab in 150 mg and 300 mg doses in patients with chronic spontaneous urticaria
حسب: Fikriye Kalkan, وآخرون
منشور في: (2025-03-01)

Efficacy of omalizumab treatment for patients with chronic idiopathic urticaria (CIU)/chronic spontaneous urticaria (CSU) in Taiwan
حسب: Che-Wen Yang, وآخرون
منشور في: (2017-12-01)

Protocolo de retiro de Omalizumab en Urticaria crónica espontánea: Caso clínico
حسب: Daniela Ramirez Vazquez, وآخرون
منشور في: (2025-09-01)

Omalizumab for chronic urticaria in Latin America
حسب: Paul Wilches, وآخرون
منشور في: (2016-11-01)